TTN and myasthenia gravis: In the EOMG, AChR-MG and Titin-MG subgroups, there was a difference in clinical severity between the early and delayed immunotherapy groups for the most severe form of the disease (p < 0.05), and early immunotherapy groups reduced the maximum oral GC dose in MG patients (p < 0.05).